Skip to main content

Advertisement

SpringerLink
Log in

Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163–168.

    Article  CAS  Google Scholar 

  2. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935–942.

    Article  CAS  Google Scholar 

  3. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485–493.

    Article  CAS  Google Scholar 

  4. Bullock JM, Noory C, Men A, Ramchandani R, Kenna L . Clinical pharmacology review: sprycel, dasatinib. Application number 21–986. US Food and Drug Administration, Center for Drug Evaluation and Research. 2006.

  5. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204–3212.

    Article  CAS  Google Scholar 

  6. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520–2526.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology, Centre for Cancer Biology, IMVS, Adelaide, Australia

    D K Hiwase, D L White, V A Saunders, S Kumar, J V Melo & T P Hughes

  2. Department of Medicine, Faculty of Health Science, University of Adelaide, Adelaide, Australia

    D K Hiwase, D L White, S Kumar, J V Melo & T P Hughes

Authors
  1. D K Hiwase
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D L White
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V A Saunders
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J V Melo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T P Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T P Hughes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hiwase, D., White, D., Saunders, V. et al. Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells. Leukemia 23, 1205–1206 (2009). https://doi.org/10.1038/leu.2009.45

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.45

  • Springer Nature Limited

This article is cited by

Search

Navigation